丨证券研究报告丨 行业研究丨点评报告丨媒体Ⅱ [Table_Title] AI 系列跟踪（85）：OpenAI 正式发布 GPT-5.2， 通义万相 2.6 全面上线 报告要点 [Table_Summary] 12 月 12 日，GPT-5.2 全面上线，包括 GPT-5.2 Instant、GPT-5.2 Thinking 和 GPT-5.2 Pro 三个版本。12 月 16 日，通义万相正式发布 Wan 2.6 系列模型，上线国内首个角色扮演功能。 在 AI 细分赛道中，我们看好：1）优质 IP 或受益于 AI 技术演进带来的创作效率和变现价值提 升，看好受益于多模态加速的 AI 漫剧赛道；2）具备流量&模型&数据优势的互联网大厂；3） 海外已跑通商业模式，国内有望复制（广告、电商、教育等）的垂直赛道；4）AI+游戏厂商。 分析师及联系人 [Table_Author] SAC：S0490516080001 SFC：BUX177 高超 朱子愉 请阅读最后评级说明和重要声明 %% %% 1 [Table_Title AI 系列跟踪（2]85）：OpenAI 正式发布 GPT-5.2， 通义万相 2.6 全面上 ...

金融工程丨点评报告 [Table_Title] A 股行业投资者结构变迁 报告要点 [Table_Summary] 《上海证券交易所统计年鉴（2025 卷）》已于近日发布，截至 2024 年，一般法人、自然人投 资者和专业机构（包含沪股通）市值占比分别为 57.22%、22.40%和 20.38%。大类行业中，金 融和周期的机构占比相对较高，二者的机构占比均在震荡提升。一级行业中，银行和非银的机 构占比较为显著，均在 70%以上。 分析师及联系人 [Table_Author] 刘胜利 SAC：S0490517070006 SFC：BWH883 请阅读最后评级说明和重要声明 丨证券研究报告丨 %% %% %% %% research.95579.com 1 [Table_Title2] A 股行业投资者结构变迁 [Table_Summary2] 事件描述 《上海证券交易所统计年鉴（2025 卷）》于 2025 年 12 月发布，由此可分析不同行业的投资者 结构变化。 事件评论 2、投资者机构持仓数据为节点信息，不代表全部调仓行为。 更多研报请访问 长江研究小程序 丨证券研究报告丨 cjzqdt11111 202 ...

Investment Rating - The industry investment rating is "Positive" and maintained [6] Core Insights - The report highlights a significant trend in downstream demand for AI applications, driven by the recent launch of the Doubao model 1.8 and the Seedance 1.5 pro video creation model at the Huoshan Engine's Winter Force Conference [2][4] - The Doubao model's daily token usage has surged to over 50 trillion, marking a 471-fold increase since its launch and more than a tenfold increase year-on-year, indicating strong demand across various industries [9] - The introduction of a "savings plan" for models, offering discounts of up to 47%, aligns pricing strategies with customer usage patterns, enhancing affordability and encouraging innovation [9] Summary by Sections Event Description - On December 18, Huoshan Engine held the Winter Force Conference, where the Doubao model 1.8 and Seedance 1.5 pro were officially launched, sparking extensive market discussions [4] Event Commentary - The report emphasizes the explosive growth in the usage of the Doubao model, reflecting genuine customer needs and the model's ability to empower various sectors [9] - The Doubao model 1.8 features enhanced multimodal capabilities, including increased video frame understanding and improved agent functionalities, which are expected to unlock more application scenarios [9] - The conference also introduced several upgraded AI agent products aimed at delivering tangible value to enterprises, such as the AgentKit platform and various specialized agents [9] - The report anticipates a further increase in industry token usage next year, particularly in multimodal applications and edge devices [9]

丨证券研究报告丨 中国经济丨点评报告 [Table_Title] 年末财政有多少余粮？ ——11 月财政数据点评 报告要点 [Table_Summary] 1-11 月广义财政收入、支出累计同比分别回落至-0.2%、4.5%。第一本账收入中，税收当月同 比连续 8 个月为正，非税收入当月同比因高基数大幅回落。第一本账支出当月同比降幅收窄， 科技、卫生健康支出走强，基建类支出仍在压降。卖地收入当月同比仍大幅下行，但基金支出 加快投放力度。广义财政收入、支出累计同比均弱于年初预算，年末财政或留有一定余粮，往 前看，12 月是财政支出大月，无论年末财政余粮是在 12 月形成支出，还是结余至 2026 年形 成支出，预计均将对 2026 年上半年稳增长形成一定支撑。 分析师及联系人 [Table_Author] 于博 宋筱筱 SAC：S0490520090001 SAC：S0490520080011 SFC：BUX667 SFC：BVZ974 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 [Table_Title 年末财政有多少余粮？ 2] ——11 月财政数据点评 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Insights - The company’s subsidiary, Beina Hong Kong, plans to sell 80% of its subsidiary Beina Belgium to Rexam Limited (100% owned by Ball Corporation) for an estimated adjusted transaction price of approximately €50-60 million, which has already received German antitrust approval [2][4] - Beina Belgium primarily produces and sells two-piece metal can packaging containers, with projected net profits of €1.79 million and €4.93 million for the first half of 2024 and 2025, respectively [2][4] - This transaction aligns with the company's overseas business development strategy, optimizing asset structure and enhancing operational efficiency [10] - The company is accelerating its overseas expansion through mergers and acquisitions and self-built factories, with a total planned capacity of approximately 4 billion cans across various regions [10] - Recent expectations for price increases in the domestic two-piece can market are optimistic, with potential recovery in profitability anticipated starting in early 2026 [10] - The company is positioned as a leader in the domestic metal packaging industry, with significant growth drivers expected from the recovery of two-piece can margins, overseas business expansion, and improved domestic consumption demand [10] Financial Projections - The company is expected to achieve net profits attributable to shareholders of ¥1.15 billion, ¥1.22 billion, and ¥1.45 billion for the years 2025, 2026, and 2027, respectively, corresponding to PE ratios of 13, 13, and 11 times [10]

%% %% 联合研究丨行业点评 [Table_Title] 本轮商业航天行情较此前有何异同？ %% %% research.95579.com 1 丨证券研究报告丨 报告要点 [Table_Summary] 不同点：催化密度和影响更大。11 月海外 AI 大厂导流，太空数据中心潜在应用场景，商业闭 环。25 年底-26 年初火箭可回收试验密集，任一公司成功均会对产业节奏造成提速。相同点： 高弹性+抗通缩选股逻辑。资本开支不会无限扩张且持续时间较短，当下单星价值量/份额高， 财务基数小的公司弹性更好。商业航天的产业中长期主旋律是通缩，而相控阵天线、太阳翼电 源等是影响通信卫星性能的核心环节，用量提升带来更好的抗通缩性。 分析师及联系人 [Table_Author] 于海宁 王贺嘉 杨洋 SAC：S0490517110002 SAC：S0490520110004 SAC：S0490517070012 SFC：BUX641 SFC：BUX462 SFC：BUW100 张弛 宗建树 高伊楠 SAC：S0490520080022 SAC：S0490520030004 SAC：S0490517060001 SFC：BUT ...

Investment Rating - The report maintains a "Positive" investment rating for the insurance sector [11]. Core Insights - In the short term, investment yield is the dominant factor for valuation, while asset allocation ratio is the decisive factor for investment yield. In the medium to long term, the spread between the asset and liability sides of insurance is expected to improve due to policy and market changes, with sufficient long-term space in the industry leading to continuous improvement in ROE [3][9]. - Recommended stocks include China Life, New China Life, Ping An, and China Pacific Insurance as quality targets [3][9]. Summary by Sections 2025 Review - The insurance sector's performance was generally flat compared to the market, with the CSI 300 index rising by 15% and the Yangtze Insurance Index increasing by 14.5%, underperforming the market by 0.6 percentage points. Individual stocks like Ping An, New China Life, and China Pacific outperformed the market [6][23]. - The liability side is undergoing a transformation towards dividends, with new policy growth slightly slowing but value rates improving, driving new business value growth. The asset side performed well due to strong equity market performance, contributing to good total investment returns [6][23]. Investment Yield Analysis - The primary determinant of insurance companies' investment yield is asset allocation. As of Q3 2025, listed insurance companies had total investment assets exceeding 20 trillion yuan, indicating that investment yield is mainly influenced by asset allocation rather than significant and sustained alpha generation [6][39]. - Even in an extremely low-interest-rate environment, yields can remain above 2%, demonstrating that the risk of spread loss for listed insurance companies is minimal [6][39]. Pricing of the Insurance Sector - Over the past decade, expected investment yield has been the anchor for insurance industry valuation. The short-term valuation is primarily influenced by yield expectations, as the liability cost rate fluctuates less in the short term [7][71]. - The report emphasizes that the asset side, particularly equity assets, has a stronger influence on investment yield than the liability side, which has limited impact due to its long-term nature [7][71]. Future Demand and Market Dynamics - The report anticipates that insurance demand will remain high in 2026, driven by a significant amount of fixed deposits and wealth management products maturing. The comparative advantage of insurance products in terms of yield is expected to attract funds from fixed deposits without requiring an increase in risk appetite [8][84]. - The industry landscape is expected to continue improving, with leading listed insurance companies benefiting more from this trend [8][84].

Group 1: Dividend Index Changes - The recent rebalancing of the dividend indices, including the CSI Dividend and Low Volatility Dividend indices, indicates a shift towards "quality dividend" assets, reflecting a trend from traditional dividend assets[2] - The number of stocks added to the CSI Low Volatility Dividend index was 18, while the CSI Dividend index saw 20 stocks added, showing a higher turnover rate in the Low Volatility Dividend index[20] - The weight of quality dividend assets has marginally increased in the Low Volatility Dividend index, suggesting a transition towards quality-focused investments[6] Group 2: Sector and Dividend Yield Changes - New sectors such as healthcare, non-metal materials, and public utilities have been added to the indices, indicating a diversification of included industries[6] - The weight of stocks with dividend yields between 5% and 8% has significantly increased in the CSI Dividend index after adjustments[7] - The CSI Low Volatility Dividend index has also seen a notable increase in the proportion of stocks with dividend yields above 5%[30] Group 3: Market Conditions and Investment Strategy - The report suggests that in a declining interest rate environment, bond-like and stable dividends are more beneficial, while quality and cyclical dividends perform better in a rising interest rate and liquidity phase[8] - The analysis indicates that the quality dividend assets are better suited for a stable or rising interest rate environment, enhancing their investment appeal[36]

Group 1: Core Insights - The "14th Five-Year Plan" achievements are the foundation for the "15th Five-Year Plan," which aims to connect to the 2035 vision, focusing on technological innovation as the core driver for activating the domestic market and ensuring strategic security for high-quality development [3] - The "15th Five-Year Plan" emphasizes self-reliance in technology, enhancing original innovation, and laying out future industries to create new engines for development [6][35] - The plan aims to establish a unified national market and boost consumption to activate internal dynamics, providing a solid foundation for economic growth [7] Group 2: Technological Innovation - High-tech manufacturing shows resilience, with the share of the "three new economies" (new industries, new business formats, new models) in GDP steadily increasing, making technology a core engine for economic growth [15] - The "15th Five-Year Plan" suggests accelerating the development of strategic emerging industries such as new energy, new materials, aerospace, and low-altitude economy [6][35] - The transition from traditional to new energy vehicles indicates that the latter has moved past its explosive growth phase, while industries like robotics are on the verge of significant penetration [24][29] Group 3: Domestic Circulation - A strong domestic market is crucial for China's modernization, with the "15th Five-Year Plan" focusing on enhancing the internal dynamics and reliability of domestic circulation [7][55] - The plan proposes a unified national market as a key strategy to strengthen the domestic market, addressing competition issues and restoring industry profits to normal levels [55] - The focus on quality upgrades in key industries aims to consolidate and enhance the competitiveness of sectors like mining, metallurgy, and textiles in the global division of labor [55] Group 4: Strategic Security - The "15th Five-Year Plan" emphasizes building security barriers in three areas: industrial security, national defense security, and trade security, enhancing the national security system and capabilities [8] - Key areas of focus include original innovation, core technology breakthroughs, and improving the self-control level of industrial chains [8] - The plan also highlights the importance of expanding institutional openness and maintaining a multilateral trade system to address uncertainties in the global trade environment [8]

Investment Rating - The report maintains a "Positive" investment rating for the medical device industry [3]. Core Insights - The medical device industry is expected to return to positive growth in 2025 after two consecutive years of decline in 2023 and 2024, driven by increased demand for hospital equipment due to equipment renewal policies [10]. - Monthly procurement data shows a continuous recovery trend, with November 2025 procurement amounting to 208.76 billion yuan, reflecting a month-on-month increase of 26.93% [18]. - The domestic production rate of medical devices has increased from 19% in 2019 to 48% in November 2025, indicating a significant shift towards local manufacturing [21]. Summary by Sections Equipment Procurement - The medical device procurement is showing a sustained recovery, with a projected annual procurement scale for 2025 estimated between 1,884 billion yuan and 2,422 billion yuan based on the first half's performance [14]. - The procurement amount for November 2025 was 208.76 billion yuan, with a year-on-year decrease of 0.25% but a month-on-month increase of 26.93% [18]. Market Segmentation - The procurement scale for ultrasound devices in November 2025 reached 22.40 billion yuan, showing a year-on-year growth of 17.60% and a month-on-month growth of 41.67% [27]. - CT device procurement in November 2025 was 25.36 billion yuan, with a year-on-year increase of 27.58% and a month-on-month increase of 22.82% [28]. - MRI procurement in November 2025 was 23.94 billion yuan, reflecting a year-on-year growth of 5.68% and a month-on-month growth of 29.94% [31]. - Digestive endoscope procurement in November 2025 was 7.30 billion yuan, with a year-on-year increase of 3.26% and a month-on-month increase of 41% [36]. - Surgical robot procurement in November 2025 was 5.60 billion yuan, showing a year-on-year growth of 8.33% but a month-on-month decrease of 11.53% [37]. Company Performance - Mindray Medical's procurement in November 2025 was 13.18 billion yuan, with a year-on-year increase of 12.16% and a month-on-month increase of 38.34% [44]. - United Imaging's procurement in November 2025 reached 14.33 billion yuan, reflecting a year-on-year growth of 30.40% and a month-on-month growth of 31.15% [46]. - KAILI Medical's procurement in November 2025 was 2.47 billion yuan, with a year-on-year increase of 62.15% and a month-on-month increase of 17.95% [50]. - Aohua Endoscopy's procurement in November 2025 was 1.09 billion yuan, showing a year-on-year growth of 59.95% and a month-on-month growth of 62.14% [54].